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Despite the availabilityofpotentially curative interventions foratrialﬁbrillation,there remains an important rolefor conventional
anti-arrhythmic therapy and anti-coagulation combined with direct current cardioversion. Unfortunately, the latter approach is
disturbed by high recurrence rates of atrial ﬁbrillation. In recent years, several adjunctive therapies have emerged which may
facilitate the maintenance of sinus rhythm. These novel therapies and their potential mechanisms of action are reviewed in this
article.
1.Introduction
Atrial Fibrillation (AF) is the most common sustained car-
diac arrhythmia found in clinical practice [1, 2]. Its preva-
lence increases with age and concomitant heart disease, and
it’s presence is an independent predictor of mortality [3].
Once AF is initiated, changes in the electrophysiological
properties of the atria occur which promote its perpetuation
[4, 5].
Despite new insights into the pathophysiology of AF and
the emergence of novel antiarrhythmic therapies, the man-
agement of this common cardiological condition remains
problematic. During the past decade, a number of large
randomisedtrials haveinvestigatedthemeritsofarateversus
rhythm control strategy: Pharmacological Intervention in
Atrial Fibrillation (PIAF), Strategies of Treatment of Atrial
Fibrillation (STAF), Rate Control Versus Electrical Conver-
sion (RACE), Atrial Fibrillation Followup of Rhythm Man-
agement (AFFIRM), and How to Treat Chronic Atrial Fibril-
lation (HOT-CAFE) [6–10]. None of these studies were able
todemonstrate a signiﬁcant advantage of eitherstrategy with
respect to cardiovascular morbidity and mortality, whereas
theyallrevealedanincreaseinhospitalisationassociatedwith
rhythm control, PIAF and AFFIRM also demonstrating a
signiﬁcantlyhigherincidenceofadversedrugeventsamongst
the rhythm control groups. In light of these observations,
and given the problems of proarrhythmia and toxic end
organ eﬀects experienced with conventional antiarrhythmic
medication, a consensus has emerged that rate control is at
least as eﬀective treatment option as attempting to restore
SR, particularly in certain groups of patients with signiﬁcant
comorbidity.
There remains, however, a number of theoretical advan-
tages to pursuing a rhythm control strategy where appropri-
ate, and both European and American guidelines recognise
this [11, 12]. The restoration of eﬀective atrial contraction
will result in improved diastolic performance, and, therefore,
cardiac output [13] which translates into improved func-
tional capacity and exercise tolerance [7, 8]. Furthermore,
the restoration of sinus rhythm leads to a reversal of atrial
electrical remodelling, and, hence, a reduced propensity for
the development of chronic arrhythmia [14].
Electrical external cardioversion is a well-established
treatment for persistent AF. Depending on patient selection,
it can have very high initial success rates with studies report-
ing up to 95% cardioversion success [15, 16]. The problem,
however, is not the eﬃcacy of the procedure, but the very
high subsequentrelapse rate,evenwhen conventionalantiar-
rhythmic drugsareusedadjunctively.Thishasledtogrowing
interest and exploration of alternative pharmacotherapy, not
generally thought of as directly antiarrhythmic, for the pre-
ventionof AFand the maintenance ofSRafter cardioversion.2 ISRN Cardiology
This review examines the growing body of evidence that
suggests that targeting the rennin angiotensin aldosterone
system (RAS), reducing inﬂammation, and using drugs such
as statins and fatty acids may oﬀer a legitimate approach to
the prevention of AF recurrence.
2.The ReninAngiotensin AldosteroneSystem
2.1. ACE Inhibitors and Angiotensin II Type 1 Receptor Block-
ers. Angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin II type 1 receptor blockers (ARBs) improve
prognosis in patients with underlying cardiac disease such as
chronic heart failure (CHF), ischaemic heart disease (IHD),
and hypertension (HT) [17–23] irrespective of cardiac
rhythm at the outset of treatment. Indeed, it was the obser-
vation of the potential abilityo fA C E I st op r o t e c ta g a i n s t
the development of AF in clinical trials of CHF [24, 25]
and postinfarction left ventricular (LV) dysfunction [26]
that aroused interest in this area. Pedersen et al. [26], for
example, in a study evaluating the role of ACEIs in patients
with CHF observed that trandolapril reduced the risk of
developing AF by 55%. More recently a meta-analysis has
shown that in over 24,000 patients with either HT, CHF,
or IHD treatment with ACEIs/ARBs markedly reduces the
risk of development of AF [27]. There is also evidence to
suggestthat targeting RASpreventsAFrelapse after electrical
cardioversion. In a study by Madrid and colleagues [28],
the addition of irbesartan to amiodarone achieved better
maintenance of sinus rhythm than amiodarone alone during
long-term followup after DCCV. Similarly, Ueng et al. [29]
showed that adding enalapril to amiodarone was more
eﬀectiveatmaintaining SRat4weeksthanamiodaronealone
(P = 0.002).In both studies, there was a trend towards lower
rate of immediate recurrence in the combination treatment
group, with most of the beneﬁt being seen within the ﬁrst 8
weeks following cardioversion
ACEIs and ARBs appear to have potentially beneﬁcial
eﬀects on AF conversion and SR maintenance by interaction
with the deleterious structural and electrical remodelling
processes that can occur with AF. Three mechanisms have
beensuggestedtoexplaintheirantiarrhythmic actionsinAF:
(1) reduced atrial stretch and reversal of atrial structural
remodelling,
(2) suppressed angiotensin-II-induced ﬁbrosis,
(3) modulation of ion channel function and reversal of
atrial electrical remodelling.
2.1.1.ReducingAtrialStretch. Raisedatrialpressureincreases
vulnerabilityto arrhythmia byshortening refractory periods,
through the opening of stretch-activated ion channels. In
animal studies of congestive heart failure (CHF), it has
been shown that atrial stretch induces action potential
shortening and delayed impulse propagation which predis-
pose to AF [30–34]. The haemodynamic eﬀects of ACEI
include systemic arteriolar dilatation and increased large
artery compliance that decrease systolic blood pressure. In
the setting of CHF, the inhibition of RAS reduces after-
load and systolic wall stress and decreases left atrial pressure
[35].
In the study by Ueng and colleagues [29], an LA dimen-
sion of >40mm was the only clinical parameter which pre-
dicted relapse into AF. Treatment with enalapril signiﬁcantly
reduced the recurrence of AF in these patients, implying
reversibility of structural remodelling.
2.1.2. Preventing Fibrosis. Activation of RAS leads to cardiac
ﬁbrosis in a variety of pathological conditions. Angiotensin
II possesses a growth-enhancing eﬀect on cardiac myocytes,
vascular smooth muscle cells, and ﬁbroblasts. Binding of
angiotensin II to AT1 receptors stimulates ﬁbrous tissue for-
mation by promoting TGF-β1s y n t h e s i s[ 36]. This cytokine
is activated during the development of CHF [37], and its
selective overexpression shows strong correlation with an AF
in animal studies [38]. Cardiac ﬁbrosis and in particular
interstitial ﬁbrosis is commonplace in patients with AF, and
the likelihood of AF increases with increasing extent of
ﬁbrosis [39] .A C E I sa n dA R B ’ sh a v eb e e ns h o w nt or e d u c e
atrial ﬁbrosis, conduction abnormalities, and AF promotion
while reducing atrial angiotensin II concentrations [40–42].
T h eR o l eo fA l d o s t e r o n e .Aldosterone, the ﬁnal product of
RAASactivation is also a potentstimulator of cardiac ﬁbrosis
[43]. When present in excess, it is associated with a greatly
increased risk of atrial ﬁbrillation [44].
Milliezandhiscolleagues[45]lookedattheeﬀectsofspi-
ronolactone, lisinopril, and/or atenolol on atrial arrhyth-
mias, haemodynamics, and atrial ﬁbrosis in rats with CHF.
Theyfoundthateach treatmentandcombinationsuppressed
atrial ectopy in a statistically signiﬁcant fashion, but only
spironolactone alone or in combination signiﬁcantly atten-
uated the arrhythmogenic process of atrial ﬁbrosis.
Aldosterone blockade may be a promising new approach
for atrial tachyarrhythmia prevention in CHF. Selective al-
dosterone-receptor blockade with eplerenone suppressed
inducible AF in an experimental model of heart failure [46].
Inthisstudy,eplerenonetreatment wasassociated withselec-
tive prolongation of atrial refractory periods and improved
LV diastolic ﬁlling
The placebo-controlled EPLERAF study which is cur-
rently underway will examine whether Eplerenone reduces
atrial ﬁbrillation (AF) recurrences within the ﬁrst 8 weeks
after electrical cardioversion of persistent AF.
2.1.3. Modulating Cellular Electrophysiology and Electrical
Remodelling. AF recurrence after DCcardioversion (DCCV)
can be the clinical consequence of electrical remodelling
through, for example, the eﬀects of atrial premature beats
and the shortening of eﬀective refractory periods within the
atria [4, 47]. Atrial premature beats (APBs) are a potentially
important trigger for the induction and reinitiation of AF
[48]. The ability of APBs to induce AF depends on their tim-
ing and location relative to electrical heterogeneity gradients
[49]. ACEIs and ARBs may suppress the APBs, by modi-
fying the sympathetic tone [50, 51] and altering Na+/Ca2+ISRN Cardiology 3
Table 1
Study Study design N Followup




double blind 18 1.5 Lisinopril Placebo Maintenance of SR: 71% with lisinopril
versus 36% with placebo
Madrid et al. [28] Randomised,
open label 154 2 Irbesartan No irbesartan
Reduction in the risk of AF recurrence with
irbesartan: adjusted HR (95% CI): 0.19
(0.04–0.86); P = 0.03
Ueng et al. [29] Randomised,
open label 145 9 Enalapril No enalapril
Recurrence of AF: 4.3% with enalapril
versus 14.7% without, P = 0.067.
Probability of remaining in SR at 4 weeks:
84.3 versus 61.3%, P = 0.002.
Adjusted HR (95% CI): 0.37 (0.12–1.15);
P = 0.041
Madrid et al. [27] Randomised,
open label 60 7.3 Irbesartan
(+amiodarone) No irbesartan
Patients remaining free of AF at 1yr:
irbesartan 300mg + amiodarone = 77%,
irbesartan 150mg + amiodarone = 65%,
amiodarone alone = 52% (P = 0.001 versus
irbesartan 300mg + amiodarone)
Grecu et al. [56] Randomised,
open label 36 12 Perindopril
(+Propafenone) Placebo
Maintenance of SR: 37% with perindopril
versus 20% with placebo. Time interval to
recurrences was signiﬁcantlyhigher in
ACEI-treated patients (7.06 ± 1.02 versus
4.50 ± 0.93 months;P = 0.034)
T v e i te ta l .[ 57]
(CAPRAF study)
Randomised,
double blind 137 6 Candesartan Placebo Recurrence of AF: 71% with candesartan
versus 65% with placebo P = ns
Belluzzi et al. [60] Randomised,
double blind 62 36 Ramipril Placebo
Recurrence of AF: 10% with ramipril versus





double blind 1,442 12 Valsartan Placebo
Recurrence of AF: 51.4% with valsartan
versus 52.1% with placebo.
Adjusted HR (96% CI): 0.97 (0.83–1.14);
P = 0.73
exchanger activity [52–54]. They may also attenuate eﬀective
refractory period shortening.
A recent study by Zaman et al. [55] showed that patients
listed for routine DCCV who were simultaneously taking
ACEIs had a decreased number of deﬁbrillation attempts
and decreased AF-related admission rates. Furthermore, the
investigators identiﬁed a decrease in signal averaged P-wave
duration (prolonged P-wave duration is a powerful marker
of resistant AF). Therefore, in this study, ACEIs facilitated
AF cardioversion and the maintenance of SR by modifying
the arrhythmogenic substrate.
Schneider et al. recently published a meta-analysis of 8
RCT’s which investigated the eﬀectsofRASinhibition on the
recurrence of AF after electrical or chemical cardioversion
(Table 1). Overall, they report a signiﬁcant reduction in the
risk for AF recurrence after cardioversion with the use of
ACEI’s or ARBs (OR: 0.55; 95% CI: 0.34 to 0.89; P = 0.01).
However, 4of these trials were open-label design [27–29,56],
andtheirpromisingresultswerenotreplicatedinthedouble-
blind, placebo-controlled “candesartan in the prevention of
relapsing atrial ﬁbrillation” (CAPRAF) study [57], or in the
GISSI-AF trial [58], which failed to detect any eﬀect of
treatment with valsartan on the recurrence of AF.
Further work, therefore, needs to be done in this area to
clearly deﬁne the therapeutic role of RAS blockade in AF.
Additional studies will also need to ascertain whether up-
stream blockade of the RAA axis with ACEI is superior to
downstream blockade with ARBs, or whether there is addi-
tional advantage in combining treatments.
3.The RoleofInﬂammationinAF
Inﬂammation playsapivotalroleinthepathogenesisofcoro-
nary atherosclerosis and cardiovascular disease [61], and
markers of inﬂammation such as C-reactive protein (CRP)
have been shown to be good predictors of future car-
diovascular events [62–64]. There is growing interest in
both the role that inﬂammation has in the propagation of
persistent AF and also the role of inﬂammatory indices to
predict successful cardioversion and maintenance of SR long
term.
Bruins and colleagues were the ﬁrst group to propose the
inﬂammation—AF hypothesis, following their observations
of an increased frequency of AF after coronary artery by-
pass surgery [65]. They chronologically paralleled changes in4 ISRN Cardiology
the inﬂammatory cascade resulting in complementary acti-
vation with rising incidence of atrial arrhythmias.
Since their formative work, there have been numerous
clinical studies demonstrating the relationship between in-
ﬂammation (using serum or plasma vascular inﬂammatory
markers) andAF[66–72].Chungandcolleaguesshowed that
amongst their cohort of 131 patients with atrial arrhythmias,
those with persistent AF had higher CRP levels than those
with paroxysmal AF, who in turn had higher levels than
normal controls [72].
In certain subgroups of patients, AF may primarily be
an inﬂammatory disorder, in which inﬂammatory change
acts as both the initiator, and the propagator of AF. The
presence of inﬂammatory inﬁltrates, and oxidative damage
in the atrial biopsy specimens ofpatients with lone AFis well
documented [39]. In a study by Nakamura and colleagues
[73], abnormal atrial histology was uniformly found in mul-
tiple biopsy specimens of patients with lone AF compared
with normal histology in all of the controls, with 66% of the
AF group showing evidence of occult myocarditis.
4.Corticosteroids
Given the evidence supporting the link between inﬂamma-
tion and AF, it is logical to question whether drugs with an
anti-inﬂammatory action have a therapeutic and preventa-
tive role in certain patient subsets. Dernellis and Panaretou
showed that the addition of low-dose glucocorticoid therapy
to established antiarrhythmic treatment after cardioversion
produced a dramatic reduction in AF recurrence rates
and the development of permanent AF. Their study also
conﬁrmed the predictive value of CRP measurement in such
circumstances, showing that the risk of recurrent AF was
increasedbyapproximately7timesforeach1mg/dLincrease
in plasma levels of CRP [74].
Whilst the current evidence base to advocate the use of
steroids as routine treatment for AF is absent, there appears
to be future scope for their use in maintaining sinus rhythm
following DCCV, particularly amongst those with high risk
ofrecurrence asindicated byelevatedinﬂammatory markers.
5.Statins
Statins (hydroxymethylglutaryl coenzyme A reductase inhib-
itors) have anti-inﬂammatory actions independent of their
lipid lowering eﬀect and have been shown to lower CRP [62,
75, 76]. In a retrospective study carried out by Siu et al., they
looked at 62 patients over 18 months who underwent DCCV
for lone persistent AF. At the end of a mean patient followup
of 44 months, they discovered a high overall recurrence rate
of 85%, but a signiﬁcant diﬀerence between those taking and
not taking statin therapy (40% versus 84%, P = 0.007). The
relative beneﬁtofstatin therapywas observedduringthe ﬁrst
few months after DCCV and persisted throughout followup
[77].
An u m b e ro fd i ﬀerent mechanisms by which statins help
prevent AF recurrence, in addition to their anti-inﬂamma-
tory role, can be postulated.
I s c h a e m i ai sak n o w ns u b s t r a t ef o rA F[ 78], and, there-
fore,thebeneﬁcialeﬀectstheyhaveinthissettingmaybedue
to their retardation of coronary artery disease progression. It
i sa l s op o s s i b l et h a ts t a t i n se x e r td i r e c ta n t i a r r h yt h m i ce ﬀects
by altering the fatty acid composition of cell membranes
which has a knock-on eﬀect on the function of transmem-
brane ion channels [79, 80].
6.PolyunsaturatedFattyAcids
N-3 polyunsaturated fatty acids (PUFAs), of which oily ﬁsh
are an important source, are believed to possess both anti-
inﬂammatory and antiarrhythmic eﬀects and, thus, may
have a role in the prevention and treatment of AF [81].
PUFA’s have been shown to exert anti-asynchronous eﬀects
in rat atrial myocytes, reduce proarrhythmic eicosanoids,
and inhibit sodium and calcium currents which contribute
to the arrhythmic process [82, 83]. N-3 fatty acids have also
been shown to be associated with a greatly reduced risk of
sudden cardiac death [84, 85].
Only a small number of randomised controlled studies
have been published on the therapeutic use of ﬁsh oils in
AF. In a recent study examining the role of N-3 fatty acids in
preventing AF following coronary bypass surgery; it showed
that preoperative use of PUFA’s (2g for 5 days prior to
surgery and continued until discharge) was associated with
a 54% relative risk reduction of postoperative AF [86]. This
is comparable to rates achieved with conventional antiar-
rhythmic therapy. To date, no one has looked at whether this
beneﬁt is replicated peri-DCCV.
In a prospective, population-based cohort ofover65year
olds, Mozaﬀarian and colleagues were able to demonstrate
thattheconsumptionofhighlevelsofﬁshcontainingomega-
3 fatty acids was associated with a signiﬁcantly lower inci-
dence of subsequent AF development.However, these results
were challenged by a much larger prospective cohort study
that failed to demonstrate any reduction in risk of AF or
ﬂutter associated with high consumption of omega-3 fatty
acids. Whatisclearlynowneededisarandomised-controlled
study examining the potential role of PUFA’s in preventing
recurrence of AF following successful DCCV.
7.Summary
In certain subgroups of patients with AF, successful mainte-
nance of SR has the potential to oﬀer signiﬁcant advantage
and improved clinical outcome when compared to rate con-
trol strategies. The long-term success of DC cardioversion,
however, remains poor. In this review, we have shown that
there are additive pleiotropic eﬀects of many medications
that patients already commonly take for coexisting condi-
tions associated with AF. When considering cardioverting
patients with AF, these concomitant therapies may poten-
tially facilitateSRmaintenance and,therefore,allow tailoring
of drug treatment in individual patients depending on the
underlying aetiology of their arrhythmia.
AF remains a condition for which there is still signiﬁcant
unmet need. Increased use of ablative therapy will help toISRN Cardiology 5
bridge future treatment gaps, as well as the use of upstream
therapies and novel pharmacotherapy peri-cardioversion.
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